PNT News and Press, POINT Biopharma Global Inc. From 11/24/21

INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energ...

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 INDIANAPOLIS, Nov. 22, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc....

POINT Biopharma Global (NASDAQ:PNT): Q3 GAAP EPS of -$0.19. Cash and Cash Equivalents of $252.82M Press Release For further details see: POINT Biopharma Global reports Q3 results

Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an IND/CTA for PNT2004's lead, PNT6555, in the first half of 2022 Complete...

INDIANAPOLIS and TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and IONETIX Corporation, a leading cyclotron technology and isotope manufacturin...

POINT Biopharma (NASDAQ:PNT) and Kinectrics announce a long-term supply agreement for Ytterbium-176 (Yb-176) to support the company's in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program. The input material for creating n.c.a. Lu-177 is Ytterbium-176 (Yb-176): a...

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/dec2021 INDIANAPOLIS and TORONTO, Oct. 29, 2021 (GLOBE NEWSWIRE) ...

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022 INDIANAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -...

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS, Indiana, Sept. 23, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASD...

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer Phase I/II investigator-Initiated Trial to be conducted at Weill Corn...